Home
overview

SMi group presents the launch of the inaugural Disruptive Technologies in Pharma conference taking place in London on 20th-21st January, 2020.

We are running this conference because....

McKinsey estimates that big data and machine learning could generate up to $100bn in pharma and medicine annually. There has never been a more pressing need for pharma to transition to digital as existing technologies are being disrupted by Artificial Intelligence, Machine Learning, Virtual Reality, Internet of Things and Blockchain, while newer categories such as Prescription Digital Therapeutics begin to offer truly disruptive benefits.
 

As new technologies are being incorporated into pharma it is crucial, we reflect on trends in cutting-edge innovation and explore new tech-enabled opportunities to cut costs and save time.


Partnerships are at the heart of digital transformation. Innovative approaches to partnerships are leading the way towards more effective data collection, faster R&D, seamless clinical trials and above all, more patient-centric medicine. 

  

Our conference will explore how digital is impacting – and disrupting – pharma, from the perspective of both the digital customer/consumer and the digitalisation of the product.


It’s important we look for potential solutions to solve real patient challenges, not starting with the technology and trying to find a use for it.

- Harvesting ecosystem innovation through AI, ML, VR, IoT and blockchain
- Commercialisation of digital health in pharma
- Adoption of medical devices and exploration of digital therapeutics
- Assessing agile methodologies for a strategic digital transformation
- Boosting collaboration for enhanced service design and delivery
 

Vice President/Director/Manager/Head of:

• Emerging/Disruptive Technologies
• Artificial Intelligence
• Machine Learning
• Data Science/Analytics
• Technology
• External and Internal Innovation
• Digital
• IoT
• Bioinformatics

Amgen Europe BV; AstraZeneca; Boehringer Ingelheim; Boomerang Pharma, part of Accenture Interactive; Brand 24; Chiesi; Chiesi Group - Chiesi Farmaceutici S.p.A.; Codiak BioSciences; Convosphere; Daiichi Sankyo Co Ltd; Edelman UK; GlaxoSmithKline; Grifols; GS1 AISBL; GSK; inforMed.pro; LEO Pharma A/S; Listen & Learn Research; LucidQuest; Lundbeck; Merck ; Mundipharma; NexGen Healthcare Communications; Northumbria University; Novartis; NSF Health Sciences; Pharmaphorum media; QIAGEN GmbH; Seagen; Targovax ASA; Teva Pharmaceuticals; UCB; UCB S.A.; Roche; Takeda Pharmaceuticals, BenevolentAI; Pfizer ; AstraZeneca; BERG Health; Cloud Pharmaceuticals; Proteus Digital Health; Data4Cure; e-therapeutics; Emulate; Exscientia; GnS Healthcare; Bayer; Search Digital; Sanofi; Eli Lilly

Conference programme

8:30 Registration & Coffee

9:00 Chair's Opening Remarks

Karl Hess

Karl Hess, Managing Director, OnDigitalHealth Consulting
View Bio

9:10 Disruptive Technologies: The Impact from Evolution to Revolution*

Joshua Mesout

Joshua Mesout, Senior Innovation Technologist, AstraZeneca

• Exploring the opportunities that will transform the global healthcare marketplace and assessing how to prepare for convergence in Pharma and Technologies
• Evaluating how different technological advancements such as Blockchain, Augmented Reality, Virtual Reality and IoT could impact organisational capabilities and patient enhancement
• Developing a balanced transition map that addresses the multiple and significant pros and cons facing the business with investments into new technologies 
 

*subject to final confirmation

9:50 Nothing Makes Sense, Except….: A Darwinian View of Disruptive Innovation in the Pharmaceutical Industry

Professor Brian D. Smith

Professor Brian D. Smith, Principal Advisor, Pragmedic Limited
View Bio

• Nonsensical changes in our markets and industry
• Grandeur in our view of the pharma and medtech sectors
• Disruptive innovation as seen from HMS Beagle
• There is nothing as practical as a good theory
 

10:30 Morning Coffee

11:00 What is driving the Digital Transformation of the Pharma Industry?

Dr Joseph Dalton

Dr Joseph Dalton, Global Lead Digital Health Solutions Medical Outcomes, Novartis
View Bio

• Discussing current trends shaping the Digital Transformation in Pharma
• Outlining technologies that are key to the transformation process including discussing the potential in
o Patient Centric Clinical Trials
o Artificial Intelligence
o Data Analytics
o Virtual Reality and Mental Health
• Reflecting on the convergence of Pharma and Technology- Understanding the new PharmaTec phenomenon

11:40 Digital Therapeutics, beyond mHealth – extending digital technology’s reach in healthcare

Dan Boot

Dan Boot, Head of Digital Disruptive innovation, RB

• Introducing DTx as cutting-edge innovative therapeutics in a range of disease areas
• Addressing the need for a new approach to disease management – what are the benefits of DTx?
• Overviewing current obstacles – what is standing in the way for widespread use of DTx?
• DTx - relevance beyond pharma and into consumer healthcare
• Tackling the challenges of and building strategies for the DTx world
 

12:20 Networking Lunch

13:20 What is required for a DTx product to be successful?

Jessica Shull

Jessica Shull, European Lead, Digital Therapeutics Alliance
View Bio

• DTx definition, regulation, and general overview
• Designing a DTx solution: building integration into your business unit
• Highlighting opportunities - what advantages do DTx bring?
 

14:00 International insight into Standards for seamless adoption of Prescription Digital Therapeutics

Mark Campbell

Mark Campbell, Freelance Expert , formerly of NICE
View Bio

• Overviewing current FDA guidelines relating to PDG
• Gaining insight into European and UK perspectives - MHRA, NICE and EMA guidelines for PDG
• Evidence considerations for PDGs
• Discussing the need for aligning international regulations to ease adoption of PDG
• The importance of technical standards for acceptance of PDGs

15:10 Afternoon Tea

15:10 Innovative AI Technologies for Predicting Patient Enrolment and Optimal Forecasting of Clinical Trial’s Operation

Dr Vladimir Anisimov

Dr Vladimir Anisimov, Principal Data Scientist , Amgen
View Bio

• Assessing how the use of AI can maximise patient enrolment, deliver an optimal operational design and increase probability to meet the enrolment timeline
• Data-driven re-forecasting clinical trial operation at different stages by using innovative statistical methodologies and leveraging AI
• Discussing recent advances in risk-based data monitoring and forecasting trial enrolment performance
• Using innovative techniques for data-driven dynamical forecasting of various trial operational processes (event’s counts, follow-up patients, specific sites, costs etc.)

15:50 Enabling AI driven Drug Discovery with cutting edge ‘Disruptive’ Platform: a case study

Bhushan Bonde

Bhushan Bonde, Head of IT - Early Solution Innovation Development, UCB
View Bio

• Gaining first-hand insight into AI-enabled drug discovery opportunities in pharma
• Reviewing the disruptive technologies landscape through the eyes of an industry expert
• Reflecting on strategies for AI-driven drug discovery

16:30 Chair’s Closing Remarks and Close of Day One

Karl Hess

Karl Hess, Managing Director, OnDigitalHealth Consulting
View Bio

8:30 Registration & Coffee

9:00 Chair's Opening Remarks

Karl Hess

Karl Hess, Managing Director, OnDigitalHealth Consulting
View Bio

9:10 AI for Life

Dr Nicholas Kelley

Dr Nicholas Kelley, Data Science and AI Technical Advisor, Novartis
View Bio

• the potential of A.I. in health and the opportunities across the pharma pipeline
• concrete project examples from discovery through clinical trials and commercial, leveraging fundamental a.i. capabilities in cheminformatics, medical imaging, and NLP.
• the challenges & foundation required for data scientists to make a.i. opportunities a reality

9:50 AI-driven systems – focusing on practicalities of implementation

Peter Rutherford

Peter Rutherford, Global Medical Lead, Vifor Pharma
View Bio

• Discussing the impact of AI, ML and IoT on the pharmaceutical industry
• Developing AI-enabled tools for improving patient access – where do we start?
• Reflecting on global challenges of implementation and outlining strategies for improved incorporation
• Exploring AI for identifying patients with rare disease and achieve early diagnosis – a case study

10:30 Morning Coffee

11:00 AI-driven utilization of Real-World Evidence for R&D

11:40 Partnering for Digital Transformation – A Way Forward

Karl Hess

Karl Hess, Managing Director, OnDigitalHealth Consulting
View Bio

• Evaluating the role of pharma-digital partnering for adopting new technologies and enabling "Pharma 4.0"
• Discussing the opportunities and efficiencies in partnering to drive new capabilities and digital transformation in pharma
• Reflecting on the challenges associated with digital partnering and discussing strategies to reduce risk
• Personal reflections and lessons learned on digital partnering and the way forward

12:20 Networking Lunch

13:20 Digital Thread in Manufacturing

Ronan  Kelly

Ronan Kelly, Innovation Senior Manager, Pfizer

• How to encapsulate the idea of the digital thread into overarching digital strategy
• Which innovative technologies hold the highest potential for pharma – Case Studies
• Disruptive Technologies and the issues implementing POCs in a regulated environment
 

14:00 Value Based Healthcare; The role of technology and its implications on Pharma

Umair Aslam

Umair Aslam, e-health Lead, MSD Norway
View Bio

• The health care sector is slowly moving from volume-based care to value-based care, where healthcare providers are rewarded/reimbursed by the value or outcome they create and not based on the volume
• What are the potential implications on related industries such as Pharma, MedTech and others?
• What is the role of technology and e-Health in such a world?
• How does this affect the concept of user and patient centricity?
 

15:10 Afternoon Tea

15:10 Medical devices in the Digital Era - an Internet of Medical Things

Ian Wallace

Ian Wallace, Device Manager, Novartis Austria
View Bio

• Developing patient guidelines to ease usability of IoT wearables – opportunities for improvement
• Reflecting on experiences with patient compliance
• Looking at IoT wearables from a patient’s perspective –should generational differences be taken into account?
• Interpreting future perspectives for enhancing the patient experience

15:50 How to revolutionize R&D using blockchain

Natalia Monteiro

Natalia Monteiro, Clinical Trial Budget & Metrics Management, Takeda
View Bio

• Assessing the need for blockchain to increase transparency, efficiency and security in R&D
• Outlining the impact of blockchain on intellectual property rights and data sharing
• Discussing how blockchain can be applied to improve consent in clinical trials
• Utilizing blockchain for improved regulatory compliance and compound traceability

16:30 Chair’s Closing Remarks and Close of Day Two

Karl Hess

Karl Hess, Managing Director, OnDigitalHealth Consulting
View Bio

+

FEATURED SPEAKERS

Bhushan Bonde

Bhushan Bonde

Head of IT - Early Solution Innovation Development, UCB
Dr Joseph Dalton

Dr Joseph Dalton

Global Lead Digital Health Solutions Medical Outcomes, Novartis
Dr Nicholas Kelley

Dr Nicholas Kelley

Data Science and AI Technical Advisor, Novartis
Dr Vladimir Anisimov

Dr Vladimir Anisimov

Principal Data Scientist , Amgen
Ian Wallace

Ian Wallace

Device Manager, Novartis Austria
Jessica Shull

Jessica Shull

European Lead, Digital Therapeutics Alliance
Joshua Mesout

Joshua Mesout

Senior Innovation Technologist, AstraZeneca
Karl Hess

Karl Hess

Managing Director, OnDigitalHealth Consulting
Mark Campbell

Mark Campbell

Freelance Expert , formerly of NICE
Natalia Monteiro

Natalia Monteiro

Clinical Trial Budget & Metrics Management, Takeda
Peter Rutherford

Peter Rutherford

Global Medical Lead, Vifor Pharma
Ronan  Kelly

Ronan Kelly

Innovation Senior Manager, Pfizer
Umair Aslam

Umair Aslam

e-health Lead, MSD Norway

Bhushan Bonde

Head of IT - Early Solution Innovation Development, UCB
Bhushan Bonde

Bhushan Bonde is the Head of Innovation Development at IT-NewMeds, UCB. He received PhD in Systems Biology and Mathematical Modelling, with an interdisciplinary background of Computing, Biology and Mathematical Biology from Oxford (2006). He also had an interdisciplinary M. Tech in Bioprocess technology/Chemical Eng. (2001) and Bachelors in Pharmacy (1998) and had been working across Industry, University and Government Research Institutes with 15 years of experience in Computational Biology.

In 2014 he joined UCB in the New Medicines IT team, currently leading the data integration, Image and ‘omics’ based data management and analytics. His research interest involves biological data mining and visualization, mathematical algorithm design, High Performance Scientific Computing and simulation modelling of biological systems. In addition, he is always looking for disruptive technologies such as next generation sequencing and post NGS target validation (e.g. ENCODE), NoSQL techniques for Data Integration (Neo4j, SAP-HANA, SciDB, MongoDB), Gene Signature based mapping for Drug repurposing and Causal Reasoning for target identification, Artificial intelligence and Machine Learning for RWE, digital/sensors data and biological imaging.
 

Dr Joseph Dalton

Global Lead Digital Health Solutions Medical Outcomes, Novartis
Dr Joseph Dalton

Joe has over 25 years’ experience of Technology and Innovation and is currently leading the Development IT Digital Solutions and Innovation efforts at Novartis Business Services. Joe has had digital healthcare related start-ups previously and in 2013 was also the author of Irelands National Digital Health Strategy. Prior to this Joe worked with Intel’s Global Innovation Centre for many years and was awarded Intel’s Global “Innovator of the Year” in 2005 for his work in the development and commercialisation of digital healthcare and ambient assistive living technologies. In 2007 Joe was start-up director for Georgia Tech Research Institutes (GTRI) operations in Ireland. Joe is a lecturer in Innovation and has and is also a registered Research and Development Tax Credit assessor. Joe is a qualified psychologist and is currently working on a book in the area of human development and personal psychology.

Dr Nicholas Kelley

Data Science and AI Technical Advisor, Novartis
Dr Nicholas Kelley

Nicholas Kelley is the Data Science & A.I. advisor to the Digital Office. His role is to both identify and pair opportunities with innovative solutions across the pipeline and is leading a number of cross-company initiatives with the single goal of elevating data science at Novartis. These include organic and inorganic capability building, targeted external engagement, community building and new modes of operating to empower data scientists to impact the business in new innovative ways and better develop and attract talent - in addition to his key role in connecting and bringing in new innovative technologies.

Nick has a background as a data science practitioner with a Ph.D. in Biophysics from the Stanford School of Medicine with career experience in computational biology, chem- and bioinformatics, and most recently in the application of A.I. and machine learning in health.
 

Dr Vladimir Anisimov

Principal Data Scientist , Amgen
Dr Vladimir Anisimov

Dr Anisimov is working in pharma industry since 2002. He is currently Principal Data Scientist, Center for Design & Analysis, Amgen, UK. In the past he also worked for GlaxoSmithKline and Quintiles (IQVIA).
Vladimir started his career in academia and served for 20 years as Professor & Head of Applied Statistics Department established by himself at Kiev National University, Ukraine. Received PhD and ScDr degrees and diploma of Professor in Applied Statistics, published 200 papers and several books, supervised 24 PhD theses. Industry recognized expert in clinical trial’s modelling. Led a numerous number of various projects and some EU and UK grants.

Ian Wallace

Device Manager, Novartis Austria
Ian Wallace

Over the past nine years Ian has been working in various segments of the healthcare industry, throughout this time he has been utilizing big data, cutting-edge software and novel technology to find solutions to questions from all ranges of customers from line functions to senior management. Prior to Novartis, he worked in a variety of roles in healthcare, focusing primarily on scientific research and process optimization.

Jessica Shull

European Lead, Digital Therapeutics Alliance
Jessica Shull

Jessica is European Lead for the Digital Therapeutics Alliance. She is also Digital Health Manager on clinical trials and Big Data projects for respiratory disease at Bellvitge Hospital in Barcelona. She worked 13+ years with the WHO on digital health projects for health system strengthening. Consultancies include World Bank, mHealth app evaluation guidelines for Europe, and EU regulatory process for digital diagnostics. She has a MSc from the Medical College of Georgia, an MA form the University of Trento (Italy) and is pursuing a PhD in BioMedicine at the University of Barcelona.

 

Joshua Mesout

Senior Innovation Technologist, AstraZeneca
Joshua Mesout

Karl Hess

Managing Director, OnDigitalHealth Consulting
Karl Hess

Karl Hess is a digital health and population health management platform ecosystem builder, leader, investor and evangelist, as well as a subject matter expert on the topics of successful digital health business models, commercialization, investment and technologies, having interacted directly with hundreds of digital health companies over the last 10 years. Karl is currently Founding Managing Director of OnDigitalHealth Consulting, LLC, a specialized strategy consulting firm which he founded to serve the burgeoning and rapidly diversifying digital health industry. OnDigitalHealth Consulting provides management consulting services to any entity looking to take their digital health offering to the next level.

Mark Campbell

Freelance Expert , formerly of NICE
Mark Campbell

Mark Campbell is a senior healthcare manager with special interests in innovative technologies and health technology assessment. He now works as a freelance
expert having been responsible until March 2019 for NICE’s devices, diagnostics and digital evaluation programmes for almost 10 years. Before that he worked at Director
level in a UK NHS payer organisation and was a member of NICE’s technology appraisal committee. He originally qualified as a pharmacist and has worked in drug
and poisons information services, medicines management and medicines utilisation research. Current special interests include evidence development and evaluation of digital health technologies (DHTs), including artificial intelligence and prior to leaving
NICE he was part of the group which developed the first evidence standards for DHTs.

Natalia Monteiro

Clinical Trial Budget & Metrics Management, Takeda
Natalia Monteiro

Natalia works in Clinical Trial Budget & Metrics Management Analytics in the Vaccines Business Unit at Takeda, Switzerland. She is also member of the editorial board of Bockchain for Science where she reviews manuscripts as part of a trusted network of experts in blockchain for healthcare.
She has experience in bringing innovative ideas to fruition, including successfully implementing them. She has proven skills in analytics and data crunching using Excel and Tableau.

Peter Rutherford

Global Medical Lead, Vifor Pharma
Peter Rutherford

Peter Rutherford qualified in Medicine from Newcastle University, UK and then completed nephrology training in the UK at the Yale School of Medicine, USA, obtaining a PhD in 1994. For 11 years he was Senior Lecturer in Nephrology, Consultant Physician in the UK NHS and chaired the Guidelines Review Group at NICE. He moved to Pharma in 2007 initially at Baxter Healthcare and then Quintiles and is now Global Medical Lead for Rare Renal Diseases at Vifor Pharma in Zurich. He has a particular research interest in patient education and decision making and the use of remote monitoring with clinical decision support as well as the use of artificial intelligence in healthcare.

Professor Brian D. Smith

Principal Advisor, Pragmedic Limited
Professor Brian D. Smith

Professor Brian D Smith is the world’s leading authority on the evolution of the life sciences industry. At the University of Hertfordshire and Bocconi University, his research group uses Darwinian science to the understand the speciation of business models in the life sciences. His more than 300 articles and books include “The Future of Pharma”, “Brand Therapy”, “Darwin’s Medicine” and, most recently “Leadership in the Life Sciences”. Prior to his academic career, Brian worked in pharma and medtech for 20 years as a Research Chemist and in commercial roles. He continues to advise many of the industry’s leading firms.

Ronan Kelly

Innovation Senior Manager, Pfizer
Ronan  Kelly

Umair Aslam

e-health Lead, MSD Norway
Umair Aslam

Umair Aslam is a Health Economist and Technology Strategist with deep insights about how new technology is bringing forward solutions, tools and frameworks that are transforming the health care and the future way of operating and creating value. Currently, he is working in the pharmaceutical industry for MSD Norway, where he is leading the work to bring forward innovative digital solutions that support better patient outcomes, address system inefficiencies and drive business value.

Key Media Partners

Workshops

A Roadmap to Compliance with Technical, Evidence and Regulatory Standards
Workshop

A Roadmap to Compliance with Technical, Evidence and Regulatory Standards

Holiday Inn Kensington Forum
22nd January 2020
London, United Kingdom

Build, Buy or Partner: Maximising Your Digital Health Impact
Workshop

Build, Buy or Partner: Maximising Your Digital Health Impact

Holiday Inn Kensington Forum
22nd January 2020
London, United Kingdom

VENUE

Holiday Inn Kensington Forum

97 Cromwell Road , London, United Kingdom

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
HOTEL BOOKING FORM

Speaker List

Download

Programme Highlights

Download

Disruptive Tech in Pharma Brochure

Download

Media Partners


pharmaphorum

Key Media Partners
http://www.pharmaphorum.com

pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


Farmavita

Key Media Partners
http://www.farmavita.net/

Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers
Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.


Bio Pharma Trend

Key Media Partners
https://www.biopharmatrend.com/

BiopharmaTrend is a market and business intelligence platform for drug discovery and biotech industry, focusing on emerging areas: artificial intelligence in pharmaceutical R&D, "digitalization" of the pharma industry, and technology/business trends in pre-clinical and clinical drug development. We also publish articles, commentaries and opinions contributed by top industry professionals.

SAVE TO


Outlook Calendar  OUTLOOK CALENDAR
Google Calendar  GOOGLE CALENDAR
ICal Calendar  ICAL CALENDAR
Yahoo! Calendar  YAHOO! CALENDAR

Holiday Inn Kensington Forum

97 Cromwell Road
London SW7 4DN
United Kingdom

Holiday Inn Kensington Forum

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.

Thank you for visiting our event

If you would like to receive further information about our events, please fill out the information below.

By ticking above you are consenting to receive information by email from SMi.
Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out